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a b s t r a c t
The proﬁle of Czech AF 2012 is an epidemiological survey conducted by 197 Czech internal
medicine and cardiology specialists who aimed to provide a comprehensive view of patients
with non-valvular atrial ﬁbrillation and their treatment in the Czech Republic. Each special-
ist had to include 5 consecutive patients.
It involved 982 patients with an average age of 69.9  10.04 years. The population of men
was slightly higher (n = 543, 55.3%), especially in the under 65 years age group; women were
the majority in the age group above 75 years (44.3% of men, 55.7% of women).
One quarter (25.1%) of patients were diagnosed with atrial ﬁbrillation for less than 2 years;
23.2% for 2–5 years; 13.5% for 6–10 years, and 8.6% for more than 10 years. 20.7% of patients
had paroxysmal atrial ﬁbrillation; 58.5% indicated permanent atrial ﬁbrillation, i.e. lasting
more than one year. 58.7% of patients received medication to regulate heart rhythm; 44.0%
had another antiarrhythmic medication. 13.8% of patients used their medication once a day;
55.1% twice a day, and 29.6% three times a day. 38.7% of patients were after cardioversion,
7.9% were after ablation. 91.5% of patients received warfarin alone or as dual (1.4%) therapy.
Only 8.7% of patients had medium or severe kidney impairment. Only 7.5% of patients used
acetylsalicylic acid, 0.2% used dual antiplatelet treatment.
Only 3.0% of patients had CHADS2 = 0; 55.8% were at a medium risk (CHADS2 = 1–2), and
41.2% at a high risk (CHADS2 > 2). 22.1% had one associated condition; 27.5% had two
associated conditions; 19.8% had three associated conditions; 28.7% had four or more
associated conditions; and only 2.0% indicated no associated condition or gave no answer.
The most common associated condition was hypertension (90.2%), followed by ischemic
heart disease (50.9%) and diabetes mellitus (41.8%).
95 patients (9.7%) had a history of embolism while receiving antithrombotic therapy. 102
patients (10.4%) had a clinically signiﬁcant bleeding event while on antithrombotic therapy,
51 patients needed hospitalization.
The average frequency of INR measurements was 10.2 per year (10.4 by cardiologists, 10.1
by internal medicine specialists). 61.6% were within the INR therapeutic range of 2–3.
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Conclusion: Atrial ﬁbrillation  patients are commonly elderly, polymorbid and high-risk
patients on a pharmacological medication two to three times a day. INR monitoring was
close to the level described in large international studies, almost  2/3 of patients were within
the therapeutic range.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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.Table 1 – Age distribution in the registry Czech AF.
(p = 0.843).
Age (years) Overall
(n = 982)
Cardiology
(n = 513)
Internal medicine
(n = 469)
<65 26.3% 25.7% 26.9%
65–74 39.0% 41.1% 36.7%
75–79 16.3% 15.5% 17.2%
>80 18.4% 17.7% 19.2%Introduction
Atrial ﬁbrillation (AF) is the most common atrial arrhythmia in
humans [1]. Its incidence and prevalence has been steadily
growing. Its prevalence exponentially grows with age and can
reach up to 10% after the age of 70 [2–4]. Recently published
studies showed a triple increase in the prevalence of AF in the
past three decades after relevant adjustment to age, gender
and associated conditions. Its increase cannot therefore be
explained by the aging population alone. The data may also be
underestimated because up to 70% of paroxysmal AFs can be
asymptomatic. In the coming ﬁfty years, the number of
patients with AF is expected to grow 2.5–5 times [5–8], which
poses a big problem not just for healthcare but also for the
social and economic areas of society. AF patients not only have
a lower quality of life but also increased morbidity and
mortality rates [9–13]. The main causes of the double mortality
in AF patients are thromboembolic stroke and partially heart
failure. The risk of stroke in AF patients is 5 times higher than
in a healthy population. AF causes worsening heart failure in
patients with an underlying organic heart disorder; the
prevalence of AF in patients with NYHA class IV is up to
50% [14]. AF alone can also cause heart failure due to electrical,
structural and mechanical myocardial remodeling [15]. Suc-
cessful management of AF and the restoration of sinus rhythm
result in a partial improvement or full normalization of left
atrial function.
The main complication in AF is the occurrence of
thromboembolic events, in particular ischemic stroke which
signiﬁcantly affects morbidity and mortality rates in these
patients [9,16,17]. Data from international registers shows that
about 30% of strokes have a cardioembolic etiology, mainly AF
complications [18–20]. Up to three million people worldwide
annually suffer from a stroke caused by AF. These events tend
to be especially serious and disabling, with half of the patients
dying within a year [21–23].
Survey scope and design
National data on patients with atrial ﬁbrillation receiving a
‘‘traditional’’ antithrombotic therapy (warfarin, acetylsa-
licylic acid) is very scarce. The aim of the survey – as the
title itself indicates – was to obtain, through collecting
epidemiological and history data, a comprehensive view of
patients with non-valvular atrial ﬁbrillation in the Czech
Republic with respect to the prevention of a stroke. Patients
monitored by internal medicine specialists and cardiologists
in the Czech Republic were entered into the epidemiologicalsurvey; each physician was asked to enter 5 consecutive
patients with non-valvular atrial ﬁbrillation and treated with
warfarin and/or antiplatelet drug. The aim of the study was to
describe the quality of warfarin treatment in the Czech
republic, not the quality of the anticoagulation treatment at
all. Data collection took place in September-December 2012.
Descriptive  statistics to the processing of statistical frequency
and characteristics of the position (arithmetic mean, median)
were used for the statistical processing. Data processing
within the ﬁrst and second degree of the statistical classiﬁca-
tion was done using SPSS statistical software. The main
inclusion criteria was a history of non-valvular atrial ﬁbrilla-
tion treated with warfarin or acetylsalicylic acid. Exclusion
criteria included a signiﬁcant valvular defect, artiﬁcial valve
and clear contraindications to the treatment with warfarin or
acetylsalicylic  acid.
The primary objective was to collect relevant data on
patients with atrial ﬁbrillation receiving anticoagulation  or
antiplatelet treatment. Secondary objectives included infor-
mation on associated conditions, concomitant medication,
level of INR control, risk of stroke, occurrence of embolic and
bleeding complications, amongst others.
Collection, control, processing and analysis of obtained
data were provided by CEGEDIM CZ s.r.o. The survey was
supported by a grant provided by Boehringer Ingelheim s.r.o.,
Czech Republic. The authors have no conﬂict of interest. The
study was approved by ethic committee and each patient had
to sign informed concent.
Results
The survey was performed by a total of 197 cardiologists and
internal medicine specialists with an equal proportion of both
specialties: 103 physicians (52.3%) practised cardiology, the
others (n = 94, 47.7%) practised internal medicine. An absolute
majority (89.3%) had more than 10 years of experience.
Data for an overall 982 patients was evaluated, of which 513
(52.2%) were entered by cardiologists and 469 (47.8%) by
Fig. 1 – Classification of atrial fibrillation in the registry Czech AF 2012.
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years for both specialties.
One quarter (n = 258, 26.3%) of the patients was aged up to
64 years, 341 (34.7%) patients were older than 75 years. Table 1
shows the age distribution.
The population of men was slightly higher (n = 543, 55.3%),
without any difference between the specialties. There was a
strong predominance of men up to 65 years (64.7% of men,
35.3% of women); women were the majority in the age group 75
years and above (44.3% of men, 55.7% of women).
One quarter (25.1%) of patients were diagnosed with atrial
ﬁbrillation for less than 2 years; 23.2% for 2–5 years; 13.5% for
6–10 years, and 8.6% for more than 10 years. This data was
unknown for 29.6%. 20.7% of patients had paroxysmal atrial58,7%
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Fig. 2 – Antiarrhythmic medicationﬁbrillation; 2.1% had an isolated episode; 18.6% had paroxys-
mal AF; however, more than half of the patients had
permanent atrial ﬁbrillation, i.e. lasting more than one year
(Fig. 1).
Fig. 2 shows antiarrhythmic treatment of atrial ﬁbrillation.
First group of antiarhytmics (group II and IV) include data on
the use of beta-blockers and verapamil; the second one include
antiarhytmics group I and III (amiodarone, dronedarone,
propaphenone, ﬂecainide) and digoxin. 42.9% of patients used
inhibitors of proton pump or H2 receptors. 41% had an electric
cardioversion, 7.9% had an ablation.
Only 13.8% of patients used their medication once a day;
55.1% twice a day, and 29.6% three times a day. There was no
difference between the specialties; only the once a day use was7,9% 1,3%
%
8,0% 1,2%
36,9%
7,9% 1,5%
logical
rsion
Ablaon Not known
TOTAL (N=982 )
CARDIOLOGIST (N=513 )
INTERNIST (N=46 9)
 in the registry Czech AF 2012.
Fig. 3 – Comorbidities in the registry Czech AF 2012. CAD, coronary artery disease; NYHA, New York Heart Association
classification; TIA, transient ischemic attack.
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versus those above 75 years (8.8%). On the contrary, 23.6% of
patients aged less than 65 years and 37.2% of those over 75
years took their medication three times a day.Fig. 4 – Comorbidities – the most common combinations. DM, dia
ischemic attack.Figs. 3 and 4 show the occurrence of comorbidities. 22.1% of
patients had one associated condition; 27.5% had two
associated conditions; 19.8% had three associated conditions;
28.7% had four or more associated conditions; and only 2.0%betes mellitus; CAD, coronary artery disease; TIA, transient
Fig. 5 – Assessment of the risk of stroke using the CHADS2 score.
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shows the most common combination of comorbidities. 62.9%
of patients had normal renal function; renal insufﬁciency
occurred in 37.1%. In most cases (28.3%), this was a mild renal
insufﬁciency (CrCL = 50–80 mL/min, or 0.83–1.33 mL/s); only
7.7% of patients had a medium renal disorder (CrCL = 30 to
<50 mL/min, or 0.5 to <0.83 mL/s). 1% of patients had a severe
renal disorder (CrCL < 30 mL/min, or <0.5 mL/s).
The risk score CHADS2 was statistically evaluated using the
data in the questionnaires obtained by the physicians. OnlyFig. 6 – Anticoagulation and 3.0% of patients were without any risk; 55.8% were at a
medium risk (CHADS2 = 1–2), and 41.2% at a high risk
(CHADS2 > 2) (Fig. 5). 7.4% patients below 65 years of age,
2.6% in the age group of 65–74 years, and no patient over 75
years had CHADS2 = 0. 21.7% of patients below 65 years of age,
32.9% of patients aged 65–74 years, and 65.4% of patients over
75 years had a high risk (CHADS2 > 2). The CHA2DS2-VASc
score could not be precisely identiﬁed because of the absence
in the questionnaire of a question regarding vascular condi-
tions (more speciﬁcally, peripheral artery disease and theantithrombotic therapy.
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without considering these 2 risk factors in this scoring system,
only 1.4% of patients had a zero score; 6.3% had a score of 1 or 2,
and 92.3% of patients had a score of more than 2. The
distribution in the age group of less than 65 years was 5.4%,
23.3%, and 71.3% respectively; in the age group of 65–74 years
no patient had a zero score, 0.5% had one point, and 99.5% had
two or more points; and in the age group over 75 years 100% of
patients had a score of 2 (the age >75 years alone scores 2
points).
The assessment of bleeding risk (HAS-BLED score) in the
population under survey was not a primary objective.
Fig. 6 shows anticoagulation and antithrombotic therapy.
91.5% of patients received warfarin alone or as dual (1.4%)
therapy. Only 7.5% of those surveyed used acetylsalicylic acid
in monotherapy; 0.2% had a dual antiplatelet therapy and 0.8%
gave no answer.
95 (9.7%) of patients had an embolic event while on
antithrombotic treatment; this number increased with age,
from 6.2% of patients aged less than 65 years, through 8.1% of
patients aged 65–74 years, to 14.1% of patients >75 years. An
embolic event occurred in 68.4% of patients treated with
warfarin, 27.4% of patients treated with acetylsalicylic acid; no
answer was given for 4.2%. An ischemic stroke or transient
ischemic attack (TIA) occurred in 78.9%, a systemic embolism
in 12.6%, a hemorrhagic stroke in 4.2%, 6.3% gave no answer.Fig. 7 – Frequency of dosing adjustments for warfarin A hemorrhagic stroke was reported by internal medicine
specialists twice as much as by cardiologists (5.9% vs. 2.3%)
and was more common at a younger age (12.5% up to 65 years;
no patient aged 65–74 years, and 4.2% over 75 years).
Clinically signiﬁcant bleeding on antithrombotic therapy
was reported for 10.4% of patients (9.2% by cardiologists, 11.7%
by internal medicine specialists) in the following age groups:
9.3% up to 65 years; 8.9% between 65 and 74 years, and 12.9%
over 75 years. Bleeding led to hospitalization in exactly 50% of
patients (51 out of 102 patients with a bleeding event).
The average annual number of INR measurements was
10.2  4.93 (10.4 by cardiologists, 10.1 by internal medicine
specialists) in the following age groups: 10.3 up to 65 years; 10.5
between 65 and 74 years, and 9.9 over 75 years. The highest
number of INR measurements per patient was 32/year.
The INR monitoring frequency in the previous year was as
follows: 46.1% more than 10times; 36.4% 6–10 times; 5.8% 3–5
times; 1.8% 1–2 times; 6.3% had no measurement, 2.5% gave no
answer.
Warfarin dosing was changed in 75.7% of patients in the
previous year, of which 2.9% had more than 10 changes; 22.5%
had 6–9 changes; 33.4% had 3–5 changes; 21.8% had 1–2
changes, and 18.1% were unchanged. There was no difference
in the number of dose adjustments as regards the specialty or
patient's age and the number of INR in therapeutic range 2–3
was also similar (Fig. 7).and number of INRs within the therapeutic range.
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The ﬁrst-choice therapy in AF still remains to be pharmaco-
logical, which may be divided into antiarrhythmic therapy,
antithrombotic therapy and upstream therapy.
Antiarrhythmic therapy has usually only a temporary
effect and brings a number of adverse effects, including life-
threatening proarrhythmia [24]. The proarrhythmogenic effect
of an antiarrhythmic agent moves between 0 and 10% and
grows according to the severity of the structural damage of the
heart. Side effects of the most effective antiarrhythmic agent,
amiodarone, can be expected in up to 20% of patients. New
antiarrhythmic agents did not ﬁnd a signiﬁcant place in
clinical practice. A non-pharmacological approach, radio-
frequency catheter ablation (RFA) treatment, must be chosen
in patients who are signiﬁcantly symptomatic with a parox-
ysmal or other form of AF or who have a persistent or
permanent form of AF and are unable to achieve an adequate
atrial frequency [6,25,26]. More than a half of the surveyed
population used a medication causing bradycardia; 44% of
patients had another antiarrhythmic agent; more than 1/3 was
after an electric version; another 1/3 was after a pharmaco-
logical version, and 7.9% was after an ablation.
Most common of the upstream therapies are renin-
angiotensin-aldosterone system (RAAS) blockers, mainly
angiotensin-converting-enzyme (ACE) inhibitors and angio-
tensin II receptor blockers (ARBs) [27,28]. Patients with a
cardiovascular condition, especially those with left atrial
dysfunction, show an increased activation of the RAAS which
helps regulate water balance, minerals and vascular response
to damage and inﬂammation. A number of international
multi-centre studies have proved that ACE inhibitors and ARBs
reduce cardiovascular morbidity, mortality and prevent the
occurrence of a new AF in patients with heart failure, left
ventricular dysfunction and after heart attack, after stroke and
with present arterial hypertension. Both classes of drugs
inﬂuence the negative effect of angiotensin II on cells.
The survey focused on the proﬁle of atrial ﬁbrillation
patients receiving antithrombotic treatment with warfarin or
acetylsalicylic acid. Based on the data obtained, it is possible to
say that the average age of atrial ﬁbrillation patients in the
Czech Republic corresponds to that of the same patients as
mentioned in various surveys and studies worldwide. The
average age of the present patients was 69.9 years. In recently
published studies in patients with AF, the same ﬁgure was 71.5
years in the RE-LY study, 73 years in the ROCKET study, and 70
years in the ARISTOTLE study. Similar conclusions were
arrived at by our colleagues in Slovakia in a similar
epidemiological survey where the average age of men and
women was 65.4 years and 70.5 years, respectively. It can
therefore be concluded that the average age of AF population is
around 70 years.
Most patients (74.9%) had atrial ﬁbrillation more than 2
years and at the same time 79.2% had a persistent or
permanent AF, which conﬁrms both the insidiousness of this
disease and the unsatisfactory and problematic response to
antiarrhythmic treatment. A considerable part of the patients
had already had cardioversion; it is therefore deﬁnitely
important for clinical practice to have the possibility of usingcardioversion on a chosen anticoagulation therapy. A fre-
quently discussed question in connection with the introduc-
tion of new anticoagulants is kidney impairment. A minimum
(8.7%) of the patients in our rather populous sample had
medium or severe kidney impairment. Although it is neces-
sary to know and monitor kidney function in patients, the
survey showed that in real world severe kidney impairment is
not so common.
Another indicator of the success rate of any treatment is
compliance, and the beneﬁt of the once daily dosing frequency
is frequently mentioned in connection with the administra-
tion of not only anticoagulants. However, almost 85% of our
rather large sample of AF patients used their medication twice
daily; the same ﬁgure was even higher than 90% in the age
group over 75 years.
Notably, the occurrence of embolic (9.7%) and bleeding
(10.4%) events was similar in our survey; this ﬁnding contra-
dicts the results of clinical studies and various surveys in
routine clinical practice. In large international studies on new
oral anticoagulants (NOAs) the occurrence of bleeding com-
plications was approximately 30% higher than the occurrence
of stroke or systemic embolism, and NOAs reduced both types
of events by 20–30% [29,15,2,30,31].
On the other hand, they conﬁrmed that the most common
comorbidity in AF patients was hypertension (90.2%), which of
course increases the risk of bleeding unless it is corrected. The
occurrence of other comorbidities, such as heart failure,
ischemic heart disease or stroke, was similar to that in
recently published studies on NOAs with a comparable-risk
population. A European survey on atrial ﬁbrillation involving
5333 patients in 35 European countries also showed a similar
occurrence of comorbidities (90.0%) [20].
The ESC 2010 Guidelines for the Management of Patients
with Atrial Fibrillation still recommended acetylsalicylic acid
as an alternative to warfarin in patients with low and medium
risk for the prevention of stroke/systemic embolism [11,32,33].
The 2012 update of the ESC Guidelines already make
acetylsalicylic acid a peripheral issue in terms of the
management of AF [12]. It is recommended only for those
patients who refuse any anticoagulation treatment and
moreover is preferred in combination with clopidogrel. Antic-
oagulation treatment is considered to be the most effective
therapy in terms of the reduction of morbidity and mortality
rates. It is an important and positive outcome of our survey
that acetylsalicylic acid was used only by a minimum (7.5%) of
patients. Anticoagulation treatment of atrial ﬁbrillation
follows an assessment of the risk of stroke and risk of bleeding
in anticoagulation treatment. The likelihood of the risk of
stroke can be calculated using the CHADS2 score, or even more
precisely the CHA2DS2-VASc score. In the CHADS2 scoring
system, heart failure, hypertension, age >75 years, and
diabetes mellitus each obtain 1 point and the history of stroke
obtains 2 points, i.e. the maximum score is 6 points. Antic-
oagulation treatment is recommended at 1 or more points; if
warfarin is used, the target INR should be within 2.0–3.0. On the
other hand, the risk of bleeding is estimated using the HAS-
BLED score, where hypertension, abnormal renal function,
abnormal liver function, stroke, previous bleeding, labile INRs,
age over 65 years, and regular alcohol or drug intake each
receive one point. One of the shortcomings of these scoring
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score for both the need for anticoagulation therapy and the
risk of bleeding. Also, it should be noted that the HAS-BLED
score for determination of the risk of bleeding considers a
systolic blood pressure over 160 mmHg as hypertension, while
patients with well-managed hypertension receive no risk
point. Similarly, abnormal renal function is considered as
serum creatinine levels ≥200 mmol/L, which in most patients
would correspond to CrCL < 30 mL/min, or <0.5 mL/s. Former-
ly, non-risk patients were patients with a CHADS2 score of 0–1;
the latest guidelines already refer to non-risk patients without
the need for anticoagulation therapy as those with a zero
CHA2DS2-VASc score [11,12,33,34].
In our population, only 3% of patients had a zero CHADS2
score; 55.8% had a score of 1–2 where the current guidelines
clearly indicate anticoagulation therapy, and 41.2% had a
CHADS2 score over 2! It is evident that this distribution of risk
for our patients is standard across most health care facilities,
and it was the optimal choice also for the inclusion of patients
into the RE-LY study on dabigatran, where the average CHADS2
score was 2.1, as well as into the ARISTOTLE study on apixaban
with an identical score [30]. The newly recommended
CHA2DS2-VASc score for the assessment of a patient's risk is
even stricter, and the maximum percentage of patients not
indicated for anticoagulation treatment will be 1–2%. In our
population, only 1.4% of patients had a zero CHA2DS2-VASc if
certain risk factors which were not a part of the questioning
process (as already mentioned in section ‘‘Results’’) are
disregarded. Most (91.5%) of the patients in the sample under
survey were correctly managed with the anticoagulant
warfarin.
Currently, we are facing a watershed moment of transition
in the prevention of stroke in AF patients from warfarin, a
long-term but very unpredictable agent, to new oral antic-
oagulants. Already the 2010 Guidelines when referring to
anticoagulation treatment mentioned that if dabigatran is
approved for stroke prevention in AF, it may be considered
instead of warfarin [11]. The guideline was based on the results
of the RE-LY study published in 2009 which compared
dabigatran etexilate 150 mg and 110 mg twice daily to warfarin
in patients with atrial ﬁbrillation [15,29,35,36]. The study
involved 18,113 patients. 6015 patients of an average age of
71.4 years were randomized to receive dabigatran 110 mg;
6076 patients of an average age of 71.5 years received
dabigatran 150 mg, and 6022 patients of an average age of
71.6 years received warfarin. Two thirds of patients in all
branches were men, 1/3 had a CHADS2 score of 0–1, 1/3 of 2,
and 1/3 of 3 or higher. The RE-LY study was the ﬁrst to prove a
more efﬁcient and safer anticoagulation therapy than warfa-
rin. Dabigatran 150 mg twice daily reduced the risk of stroke
and systemic embolism by 35%, of ischemic stroke by 25%, at a
comparable occurrence of more severe bleeding but at a
signiﬁcantly lower occurrence of the feared intracranial
bleeding. The results of the further published studies, ROCKET
AF and ARISTOTLE, on NOAs resulted into the updated ESC
2012 Guidelines where NOAs are already preferred over
warfarin for most AF patients [12,37,20].
How successfully the INR is maintained within the
therapeutic range is essential for the prognosis of a patient
treated with warfarin. In our population, it was the overall61.6% (63.5% by cardiologists and 59.6% by internal medicine
specialists), which is a slightly higher level of therapeutic
control than the one mentioned in various similar surveys in
routine clinical practice. Nonetheless, it is necessary to
emphasize that the ESC 2012 Guidelines for the Management
of Patients with Atrial Fibrillation consider a value around
70% as good control with warfarin. The efﬁcacy of treatment
at a control level around 50% is almost equal to that of a
placebo [38]. The fact that control with warfarin is very
problematic is also proved by large clinical studies with a very
strict INR control. The ﬁgure in the ROCKET study was only
55%, in the ARISTOTLE study 62%, and in the RE-LY study 64%;
the control with warfarin in our survey was almost identical to
the INR control in the RE-LY study in the Czech Republic. INR
between 2–3 is recommended as the optimal time to
therapeutic range (TTR). The average time in the required
INR therapeutic range (TTR) was achieved in 62%. The
epidemiological survey in Slovakia achieved control in 56%
[18]. A most important factor in maintaining the INRs within
the therapeutic range is the patient's collaboration: a survey
in the United States showed one-year persistence on warfarin
only in 39% of patients and a clearly higher persistence of 63%
on dabigatran [39].
Conclusion
Atrial ﬁbrillation is the most common supraventricular
arrhythmia. Only patients with a zero score CHA2DS2-VASc,
i.e. men aged less than 65 years, are considered as non-risk
patients; only 1.4% of the patients in our epidemiological
survey had such a low risk. This survey on a population of AF
patients in the Czech Republic showed that the average age of
AF patients (i.e. 70 years) is comparable to the age of AF
patients in clinical studies and similar surveys worldwide. The
most common comorbidity in AF patients is hypertension;
medium or severe renal disorder is uncommon, and most
patients take medication more than twice a day. We found an
INR control level close to that described in large international
studies. However, it was at the cost of repeated INR
measurements, in average almost once a month (10 times a
year) and a rather frequent dose adjustment of warfarin. Most
AF patients are recommended for anticoagulation treatment
based on their stroke risk stratiﬁcation. The possibility to use
new oral anticoagulants is therefore highly beneﬁcial. On 1
May 2012, the ﬁrst of so-called new anticoagulants, dabigatran
etexilate (Pradaxa), was approved for reimbursement in the
Czech Republic. This drug which is the most practically tested
both in the CR and worldwide [39] has been gradually followed
by others – rivaroxaban (Xarelto), apixaban (Eliquis). AF patient
registers and similar surveys on NOAs were launched after
their introduction in routine clinical practice, and their wide
use is a matter of time.
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